ICRF-159 versus polychemotherapy in non-small cell lung cancer.
D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011929:Razoxane / Q000009:adverse effects / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use
D010879:Piperazines; D001761:Bleomycin; D011929:Razoxane; D014750:Vincristine; D004317:Doxorubicin